Natus Medical sell-off unjustified, says Roth Capital

After Natus Medical yesterday reported better than expected Q3 results but lowered its guidance slightly and the stock declined, Roth Capital is more confident in the company's ability to meet its 2013 margin targets. The firm thinks the stock's decline is unjustified in light of the company's 2013 outlook and it maintains a Buy rating.

View Comments (0)